alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › dipeptidyl

dipeptidyl

4 studies tagged dipeptidyl, dated 2015-01-01 to 2024-02-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review 2024-02-09
  2. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview 2022-07-01
  3. Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis 2021-10-29

Studies

4 studies carry this tag.

Date range

2015 to 2024

Top journals

  • Current medicinal chemistry 1
  • Frontiers in pharmacology 1
  • Journal of Ayurveda and integrative medicine 1
  • Reviews in the neurosciences 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Frontiers in pharmacology 2024-02-09 Drug development

    Insulin resistance in brain and amyloidogenesis are principal pathological features of diabetes-related cognitive decline and development of Alzheimer's disease (AD).

  2. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Reviews in the neurosciences 2022-07-01 Drug development

    Dipeptidyl peptidase 4 is a serine protease that cleaves X-proline or X-alanine in the penultimate position.

  3. Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Ayurveda and integrative medicine 2021-10-29 Drug development

    From the in silico and in vitro analysis, the current research emphasizes the consideration of Calebin A to be as a promising or lead compound for the treatment of several ailments where DPP-IV action is culprit.

  4. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2015-01-01 Drug development

    Prospective epidemiological studies suggest that type 2 diabetes is a risk factor for neurodegenerative pathologies such as Alzheimer disease, vascular dementia, and Parkinson disease.

All topic tags with their study counts